MRG003 With Gemcitabine for Second-line Advanced PDAC
NCT07685470
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Second Line Treatment
Interventions
DRUG:
becotatugvedotin plus gemcitabine
Sponsor
Peking Union Medical College Hospital